0.91Open0.91Pre Close0 Volume232 Open Interest4.00Strike Price0.00Turnover291.87%IV36.16%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.91Extrinsic Value100Contract SizeAmericanOptions Type-0.2628Delta0.0885Gamma5.23Leverage Ratio-0.0242Theta-0.0014Rho-1.38Eff Leverage0.0041Vega
Candel Therapeutics Stock Discussion
5.30+
Now Let's Get That 10.+ Back!
Let's Get 5.+
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cel...
No comment yet